Prime Medicine (PRME) Receivables (2024 - 2025)
Prime Medicine (PRME) reported Receivables of $4.6 million for Q4 2025, up 185.02% on a YoY basis from $1.6 million in Q4 2024, and up 3721.67% quarter-over-quarter from $120000.0 in Q2 2025.
Prime Medicine (PRME) Receivables (2024 - 2025) Analysis & Trends
Prime Medicine has reported Receivables for 2 years, with the latest figure at $4.6 million in Q4 2025.
- For the quarter ending Q4 2025, Receivables rose 185.02% year-over-year to $4.6 million; the trailing twelve-month figure through Dec 2025 stood at $4.6 million (up 185.02% YoY), and the FY2025 full-year result was $4.6 million, up 185.02% from the prior year.
- Receivables for Q4 2025 stood at $4.6 million, up from $120000.0 in the prior quarter.
- The five-year high for Receivables was $55.0 million in Q3 2024, with the low at $17000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Prime Medicine | 572.02 Mn | 572.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.59 Mn |
| Jun 30, 2025 | 120,000.00 |
| Mar 31, 2025 | 17,000.00 |
| Dec 31, 2024 | 1.61 Mn |
| Sep 30, 2024 | 55.00 Mn |